XML 37 R23.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Schedule of Revenue Recognized by Revenue Source

The following table provides the contract revenue recognized by revenue source for the three and nine months ended September 30, 2022 and 2021 (in thousands):


		Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Pharmaceutical Development Segment
License Agreement⁽¹⁾		$	5,103			$	176			$	5,235			$	10,786
Pharmaceutical Development and other			8				11				706				556
Total contract revenue		$	5,111			$	187			$	5,941			$	11,342

(1)	$5.0 million of milestone revenue related to Enteris’s License Agreement with Cara was received during the nine months ended September 30, 2022.

[custom:DisclosureRevenueRecognitionDetailsAbstract]


		Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Pharmaceutical Development Segment
License Agreement⁽¹⁾		$	5,103			$	176			$	5,235			$	10,786
Pharmaceutical Development and other			8				11				706				556
Total contract revenue		$	5,111			$	187			$	5,941			$	11,342

(1)	$5.0 million of milestone revenue related to Enteris’s License Agreement with Cara was received during the nine months ended September 30, 2022.

Schedule of Company's Contract Liabilities

The Company’s contract liabilities are presented as deferred revenues and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands):

Revenue Recognition (Details 2)

		September 30, 2022				December 31, 2021
Pharmaceutical Development Segment
Deferred revenue		$	8			$	185
Total contract liabilities		$	8			$	185